

# A prospective Study of Ventilator Associated Pneumonia in Neonatal Intensive Care Unit at Tertiary Care Centre

Sonia Bhatt<sup>1</sup>, Meenu Joon<sup>2</sup>, Shehraz Firoz<sup>3</sup>, Rishi Bansal<sup>4</sup>

<sup>1</sup>Associate Professor, Department of Paediatrics, FH Medical College, Tundla.

<sup>2</sup>Assistant Professor, Department of Paediatrics, KMC, Manipal.

<sup>3</sup>Assistant Professor, Department of Paediatrics, FH Medical College, Tundla.

<sup>4</sup>Senior Resident, Department of Paediatrics, FH Medical College, Tundla.

Received: July 2015

Accepted: August 2015

## ABSTRACT

**Background:** Ventilator associated pneumonia (VAP) is a common nosocomial infection which occurs in 9% to 27% of mechanically ventilated patients. It is an important cause of morbidity in ventilated patients increasing their ventilator days, increased length of stay in intensive care unit (ICU) and hospital as well as increased cost burden on patient and or family. **Methods:** This study conducted in a tertiary care centre. It is an observational prospective study. **Results:** Total 50 neonates who were ventilated more than 48 hours during this period were included in this study. From the 50 neonates nine (18%) neonates were associated with pneumonia. Organisms which isolated from the tracheal secretion were 11.1% Acinobacter, 33.4% Staphylococcus, 33.4% Klebsiella, 11.1% E. coli, 11.1% Pseudomonas. Most common organism responsible for mortality is Klebsiella (50%) & Staphylococcus (20%). **Conclusion:** This study concludes that the pathogenesis of VAP involves the micro-aspiration of oropharyngeal and/or gastric secretions that have been contaminated/colonized with pathogenic organisms. Efforts to prevent VAP are focused on early extubating and preventing aspiration. Early diagnosis and treatment help limit VAP related morbidity and mortality.

**Keywords:** Ventilator Associated Pneumonia, NICU, Organisms, Mortality.

## INTRODUCTION

Ventilator associated pneumonia (VAP) is a common nosocomial infection which occurs in 9% to 27% of mechanically ventilated patients. It is an important cause of morbidity in ventilated patients increasing their ventilator days, increased length of stay in intensive care unit (ICU) and hospital as well as increased cost burden on patient and or family. It has been reported that VAP attributes to mortality rate of 20% to 40%. VAP can be defined as a pneumonia that occurs more than 48 hours after initiation of mechanical ventilation. The bacterial pathogens responsible for the VAP vary in virulence and antimicrobial resistance, depending on the length of stay on mechanical ventilation and other risk factors such as previous antibiotic exposure. The pathogenesis of VAP is classically micro aspiration. This aspiration first leads to colonization and finally causes infections of respiratory tract as host defence mechanisms of body have been compromised. There are various non-modifiable risk factors for VAP which include geriatric age group (above 60), COPD, ARDS, head trauma, and reintubation. Along with non-modifiable there are certain modifiable risk factors as well. These include interventions, treatments and behaviors common to the ICU that positively or

negatively affect the incidence of VAP. Examples of these conditions are patient positioning, stress ulcer prophylaxis, and enteral nutrition practices.<sup>[1,2]</sup> The incidence of VAP can be reduced through careful scrutiny and proper implementation of these practices. Once symptoms and signs of VAP appear in patient, the accurate diagnosis and identification of the microorganism should be the urgent need of the treating physician and ICU team. Invasive diagnostic strategies should be used to improve the diagnostic efficiency. Early empiric broad-spectrum antibiotics have been found to improve mortality but only when the responsible pathogen has been identified. Empiric antimicrobials should be chosen after considering the patient's risk factors for multi-drug resistant bacteria as the cause of VAP. Important risk factors include mechanical ventilation longer than 5 days and previous antibiotic exposure. The spectrum of coverage should be limited after identification of causative pathogen. The identified bacteria and patient's response to treatment decide and determine the duration of treatment.<sup>[3-6]</sup>

### CDC criteria for VAP

Essential criteria Radiological criteria- two or more serial chest X-ray with new or progressive and persistent infiltration or consolidation or cavitation for 48 hours or more after starting mechanical ventilation.

Additional Criteria- Criteria 3 and at least 3 of the other criteria

1. Temperature instability
2. Total Leukocyte Count (TLC) count < 4000/mm<sup>3</sup>

### Name & Address of Corresponding Author

Dr. Sonia Bhatt  
Associate Professor,  
Department of Paediatrics,  
FH Medical College, Tundla.

3. Worsening of gas exchange or increased oxygen requirement
  4. Increased respiratory efforts (Retractions, nasal flaring)
  5. Rales, rhonchi / wheezing
  6. Cough present
  7. Heart rate <100 beats/min or >170 beats/ min
  8. Apnea, tachypnea, nasal flaring with retraction of wall or grunting
- Endotracheal secretions should be sent for culture and sensitivity of those babies who fulfill the criteria of VAP.

## MATERIALS AND METHODS

### Study population

Nine neonates were considered for this study which had ventilator associated pneumonia.

### Study Area

This study conducted in a tertiary care centre.

### Study duration

The duration of the study was six month.

### Sampling technique & Data collection

It is an observational prospective study.

### Inclusion Criteria

All neonates requiring ventilator support more than 48 hours in NICU at a tertiary care.

### Exclusion Criteria

Those neonates already suffering from pneumonia before putting on ventilator support.


### Data Analysis

Data were analyzed with Microsoft excel.

## RESULTS

**Table 1:** Number of positive cases with ventilator associated pneumonia

Total patients	No. of patients	Percentage
Positive cases	9	18%
Negative cases	41	82%
Total	50	100%




**Figure 1:** Number of positive cases with ventilator associated pneumonia

**Table 2:** Isolated organism from the tracheal secretion

Isolated organisms	Number	Percentage
Acinetobacter	1	11.1%
Staphylococcus	3	33.4%
Klebsiella	3	33.4%
E. coli	1	11.1%
Pseudomonas	1	11.1%
Total	9	100%

Total 50 neonates who were ventilated more than 48 hours during this period were included in this study. From the 50 neonates nine (18%) neonates were associated with pneumonia. Organisms which isolated from the tracheal secretion were 11.1% Acinetobacter, 33.4% Staphylococcus, 33.4% Klebsiella, 11.1% E. coli, 11.1% Pseudomonas. Most common organism responsible for mortality is Klebsiella (50%) & Staphylococcus (20%).



**Figure 2:** Isolated organism from the tracheal secretion

**Table 3:** This table showing indication of ventilation

Indication of ventilation	Percentage
Persistent Pulmonary Hypertension of newborn	5%
Hypoxic Ichaemic Encephalopathy	5%
Teratology of Fallot	3%
Seizures	3%
Apnea	7%
Meconium Aspiration Syndrome	12%
Sepsis with shock	30%
Severe	35%

## DISCUSSION

The primary objective of the present study was to find out the incidence of VAP in ventilated neonates. Secondary objectives were to find out endotracheal tube culture positivity and outcome of babies. The pathogenesis of VAP includes the micro-aspiration of oropharyngeal and/or gastric secretions that have been contaminated /colonized with pathogenic organisms. Efforts to prevent VAP are focused on early extubating and preventing aspiration. Early diagnosis and treatment help limit VAP related morbidity and mortality. An evidence-based guideline has been developed to implement practices aimed at the prevention, diagnosis, and treatment of ventilator associated pneumonia. In the present study, total 50 neonates were included in this study. From the 50 neonates nine

(18%) neonates were associated with pneumonia. Isolated Organisms from the tracheal secretion were 11.1% Acinetobacter, 33.4% Staphylococcus, 33.4% Klebsiella, 11.1% E. coli, 11.1% Pseudomonas. Most common organism responsible for mortality is Klebsiella (50%) & Staphylococcus (20%).

Some studies of neonatal VAP have microbiological criteria as their diagnostic prerequisite,<sup>[7-9]</sup> while others have considered clinical criteria along with microbiological.<sup>[10-12]</sup> Some researchers have revealed association of VAP with increased morbidity, a longer duration of MV, and a longer hospital and/or ICU stay.<sup>[13-16]</sup> Fischer et al., in their study,<sup>[17]</sup> reported an incidence of VAP of 9.6% in a neonatal and pediatric population after cardiac surgery and observed that a delay in extubation of 3.7 days might lead to VAP. Similar results were obtained by Srinivasan et al.<sup>[18]</sup>

All items involved in our proposed bundle were derived from controlled trials or health institutes recommendations for adults, children or neonatal VAP prevention.<sup>[12,19]</sup>

## CONCLUSION

This study conclude that The pathogenesis of VAP involves the micro-aspiration of oropharyngeal and/or gastric secretions that have been contaminated/colonized with pathogenic organisms. Efforts to prevent VAP are focused on early extubating and preventing aspiration. Early diagnosis and treatment help limit VAP related morbidity and mortality.

## REFERENCES

1. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. *Am J Respiratory Crit Care Med.* 2005;171:388-416
2. Bonten M, Kollef MH, Hall JB. Risk Factors for Ventilator-Associated Pneumonia: From Epidemiology to Patient Management. *Clin Infectious Dis.* 2004; 38:1141-9
3. Chan EY, Ruest A, O'Meade M, Cook D. Oral decontamination for prevention of pneumonia in mechanically ventilated adults: systematic review and meta-analysis. *Br Med J* 2007; 334 : 889-899
4. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, et al. Comparison of 8 vs.15 days of antibiotic therapy for ventilator associated pneumonia in adults: a randomized trial. *JAMA.* 2003 Nov 19;290(19):2588-98.
5. Croce MA, Fabian TC, Mueller EW, et al. The Appropriate Diagnostic Threshold for Ventilator-Associated Pneumonia Using Quantitative Cultures. *J Trauma* 2004; 56:931-936.
6. Early AS, Gracias VH, Haut E, et al. Anemia Management Program Reduces Transfusion Volumes, Incidence of Ventilator-Associated Pneumonia, and Cost in Trauma Patients. *J Trauma* 2006; 61: 1-7
7. American Thoracic Society Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and health care-associated pneumonia. *Am J Respir Crit Care Med.* 2005;171:388-416.
8. Kollef MH. Prevention of hospital-associated pneumonia and ventilator associated pneumonia. *Crit Care Med.* 2004;32:1396-405.
9. Resar R, Pronovost P, Haraden C, Simmonds T, Rainey T, Nolan T. Using a bundle approach to improve ventilator care processes and reduce ventilator-associated pneumonia. *Jt Comm J Qual Patient Saf.* 2005;31(5):243-8
10. Lorente L, Blot S, Rello J. Evidence on measures for the prevention of ventilator-associated pneumonia. *Eur Respir J.* 2007;30:1193-207.
11. Omrane R, Eid J, Perreault MM, Yazbeck H, Berbiche D, Gursahaney A, et al. Impact of a protocol for prevention of ventilator-associated pneumonia. *Ann Pharmacother.* 2007;41:1390-6.
12. Gastmeier P, Geffers C. Prevention of ventilator-associated pneumonia: analysis of studies published. *J Hosp Infect.* 2004;67:1-8.
13. Gautam A, Ganu SS, Tegg OJ, et al. Ventilator-associated pneumonia in a tertiary paediatric intensive care unit: a 1-year prospective observational study. *Crit Care Resusc* 2012; 14: 283-289.
14. Gauvin F, Lacroix J, Guertin MC, et al. Reproducibility of blind protected bronchoalveolar lavage in mechanically ventilated children. *Am J Respir Crit Care Med* 2002; 165: 1618-1623.
15. Blot S, Rello J, Vogelaers D. What is new in the prevention of ventilator-associated pneumonia? *Curr Opin Pulm Med* 2011; 17: 155- 159.
16. Vanlaere I, Libert C. Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock. *Clin Microbiol Rev* 2009; 22: 224-239.
17. Fischer JE, Allen P, Fanconi S. Delay of extubation in neonates and children after cardiac surgery: impact of ventilator-associated pneumonia. *Intensive Care Med* 2000; 26: 942-949.
18. Srinivasan R, Asselin J, Gildengorin G, Wiener-Kronish J, Flori HR. A prospective study of ventilator-associated pneumonia in children. *Pediatrics* 2009; 123: 1108-1115
19. Kollef MH. Prevention of hospital-associated pneumonia and ventilator associated pneumonia. *Crit Care Med.* 2004;32:1396-405.

**How to cite this article:** Bhatt S, Joon M, Bansal R, Firoz S. A prospective Study of Ventilator Associated Pneumonia in Neonatal Intensive Care Unit at Tertiary Care Centre. *Ann. Int. Med. Den. Res.* 2015;1(2):124-26.

**Source of Support:** Nil, **Conflict of Interest:** None declared